From: Impact of statins and ACE inhibitors on mortality after COPD exacerbations
Variables | Users of statins or ACE inhibitors (N = 4711) | Non-users (N = 6501) | P-value |
---|---|---|---|
Age (mean, SD) | 73.5 (5.4) | 74.3 (5.8) | <0.0001 |
Men | 4616 (98) | 6377 (98) | 0.7 |
Race | |||
White | 3829 (81) | 5397 (83) | |
Black | 653 (45) | 785 (54) | |
Hispanic | 124 (3) | 176 (3) | 0.04 |
Married | 2219 (47) | 2492 (39) | <0.0001 |
Charlson Comorbid Conditions | |||
Myocardial infarction | 956 (20) | 568 (9) | <0.0001 |
Congestive heart failure | 2565 (54) | 2001 (30) | <0.0001 |
Peripheral vascular disease | 881 (19) | 880 (14) | <0.0001 |
Stroke | 867 (18) | 819 (13) | <0.0001 |
Peptic ulcer | 368 (8) | 493 (8) | 0.7 |
Rheumatologic disease | 125 (3) | 158 (2) | 0.5 |
Mild liver disease | 40 (0.8) | 82 (1) | 0.04 |
Dementia | 156 (3) | 324 (5) | <0.0001 |
Diabetes | 1678 (36) | 1324 (20) | <0.0001 |
Diabetes with complications | 488 (10) | 258 (4) | <0.0001 |
Moderate Liver disease | 19 (0.4) | 36 (0.6) | 0.3 |
Hemiplegia | 72 (2) | 70 (1) | 0.04 |
Renal disease | 480 (10) | 393 (6) | <0.0001 |
Any malignancy | 913 (19) | 1373 (21) | 0.02 |
Metastatic solid tumor | 134 (3) | 245 (4) | 0.008 |